key: cord-0875108-9pu8fc7d
authors: Monaghan, C.; Larkin, J. W.; Chaudhuri, S.; Han, H.; Jiao, Y.; Bermudez, K. M.; Weinhandl, E. D.; Dahne-Steuber, I. A.; Belmonte, K.; Neri, L.; Kotanko, P.; Kooman, J. P.; Hymes, J. L.; Kossmann, R. J.; Usvyat, L. A.; Maddux, F. W.
title: Artificial Intelligence for COVID-19 Risk Classification in Kidney Disease: Can Technology Unmask an Unseen Disease?
date: 2020-06-17
journal: nan
DOI: 10.1101/2020.06.15.20131680
sha: 22339fbf6d272c9a16ba817569ca4fe3ea38c35f
doc_id: 875108
cord_uid: 9pu8fc7d

Background: We developed two unique machine learning (ML) models that predict risk of: 1) a major COVID-19 outbreak in the service county of a local HD population within following week, and 2) a hemodialysis (HD) patient having an undetected SARS-CoV-2 infection that is identified after following 3 or more days. Methods: We used county-level data from United States population (March 2020) and HD patient data from a network of clinics (February-May 2020) to develop two ML models. First was a county-level model that used data from general and HD populations (21 variables); outcome of a COVID-19 outbreak in a dialysis service area was defined as a clinic being located in one of the national counties with the highest growth in COVID-19 positive cases (number and people per million (ppm)) in general population during 22-28 Mar 2020. Second was a patient-level model that used HD patient data (82 variables) to predict an individual having an undetected SARS-CoV-2 infection that is identified in subsequent [≥]3 days. Results: Among 1682 counties with dialysis clinics, 82 (4.9%) had a COVID-19 outbreak during 22-28 Mar 2020. Area under the receiver operating characteristic curve (AUROC) for the county-level model was 0.86 in testing dataset. Top predictor of a county experiencing an outbreak was the COVID-19 positive ppm in the general population in the prior week. In a select group (n=11,664) used to build the patient-level model, 28% of patients had COVID-19; prevalence was by design 10% in the testing dataset. AUROC for the patient-level model was 0.71 in the testing dataset. Top predictor of an HD patient having a SARS-CoV-2 infection was mean pre-HD body temperature in the prior week. Conclusions: Developed ML models appear suitable for predicting counties at risk of a COVID-19 outbreak and HD patients at risk of having an undetected SARS-CoV-2 infection.

The 2019 coronavirus disease pandemic is challenging the world's healthcare systems, including bringing complexities to maintenance of dialysis in people with end stage kidney disease (ESKD) (1) (2) (3) (4) (5) . In the United States, most ESKD patients are treated by outpatient hemodialysis (HD) where social distancing can be difficult and heightened infection control measures are required (e.g. temperature screenings, double-masking, isolation treatments/shifts/clinics) (1) (2) (3) (4) (5) . ESKD patients are typically older and have multiple comorbidities, placing the population at higher risks for requiring intensive care and dying if affected by COVID-19 (6) (7) (8) (9) (10) (11) (12) .

Early reports from the United States show an 11% COVID-19 mortality in ESKD (13) , which is higher than the 3.2% COVID-19 mortality in the national population (14) . This is not unexpected with reports from China and Europe suggesting a 16% and 23% COVID-19 mortality in ESKD (15, 16) . Albeit the high mortality rate, an impaired immune response may render dialysis patients more frequently asymptomatic when infected by SARS-CoV-2 (15, 16) . In both the general and EKSD populations, the most prevalent symptoms of COVID-19 at presentation are fever (11%-66% dialysis & 82% general population) and cough (57% dialysis & 62% general population) (15, 17, 18) . The less frequent occurrence of signs and symptoms indicative of COVID-19 in dialysis patients could be making the outbreak even more challenging to manage.

Dialysis providers routinely capture patient/clinical data during care. The robust data collected during HD treatments (generally thrice weekly) provide unique opportunities to leverage artificial intelligence (AI) in predicting COVID-19 outcomes. AI modeling helped identify onset of the outbreak in China (19, 20) and is currently being used to help with early detection of areas/individuals in the general population at risk of being affected by COVID-19 (21) (22) (23) .

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06. 15.20131680 doi: medRxiv preprint As part of an healthcare operations effort in response to the COVID-19 outbreak, an integrated kidney disease healthcare company aimed to develop two unique machine learning (ML) prediction models that identify risk of: 1) a major COVID-19 outbreak in a dialysis service county, and 2) a HD patient having an undetected severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. We analyzed the performance of these models to determine their possible utility for testing in the HD population.

General:

An integrated kidney disease healthcare company (Fresenius Medical Care, Waltham, MA, United States) used COVID-19 data on the general United States population and HD patient data from a national network of dialysis clinics (Fresenius Kidney Care, Waltham, MA, United States) to develop two unique ML models that predict risk of: 1) a major COVID-19 outbreak in the county of dialysis clinic(s) servicing a local HD population in the following week (7 days), and 2) an adult HD patient having an undetected SARS-CoV-2 infection that is identified after the following ≥3 days.

This analysis was performed in adherence with the Declaration of Helsinki under a protocol reviewed by New England Independent Review Board (NEIRB). This retrospective analysis was determined to be exempt and did not require consent (Needham Heights, MA, United States; NEIRB#1-17-1302368-1).

County Population and COVID-19 Outbreak:

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06. 15.20131680 doi: medRxiv preprint For construction of a model to predict a major COVID-19 outbreak in the county for a local HD population, we obtained data on daily COVID-19 positive (COVID-19+) cases in each United States county during 14-28 Mar 2020 from The New York Times COVID-19 dataset (The New York Times Company, New York City, United States) (24) . We also captured data on the total United States county population (25). We used retrospective county-level data from local HD populations at the national network of clinics from 08-28 Mar 2020.

We used data from all counties with ≥1 dialysis clinic and >5 HD patients. The outcome of a major COVID-19 outbreak in a dialysis service area (county) was defined was defined by a clinic being located in one of the top 300 national counties that had a combination of the highest (a) growth rate in COVID-19+ cases (number and people per million (ppm)) in the general population, and (b) highest number of COVID-19+ cases ppm in the last week of the observation period (22-28 Mar 2020) .

For the construction of a model to predict individuals with an undetected SARS-CoV-2 infection, we considered data from adult (age ≥18 years) HD patients treated in the national network. Positive arm included data from patients who had ≥1 laboratory (rRT-PCR) confirmed COVID-19+ test as of the end of the observation period (27 Feb 2020 through 04 May 2020). Negative arm included data from patients who: 1) resided in counties with no reported COVID-19 cases as of 12 April 2020, and/or 2) had been laboratory tested and were found COVID-19 negative.

We defined the index date of a HD patient having a SARS-CoV-2 infection as the date of the first recorded suspicion that led to a COVID-19+ test, or the date of the COVID-19+ test in patients without an earlier recorded suspicion. In control patients with a negative COVID-19 test result, the test date was used as the index date. In controls without a test (patients living in counties with no reported cases), the . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131680 doi: medRxiv preprint index date was randomly sampled from the positive cases' index dates occurring before 30 March 2020.

This cutoff was chosen to minimize the possibility that control patients were infected but not tested (or reported) until after the date defining negative counties of 12 April 2020. We included data from patients with 1) ≥1 laboratory (of any kind) collected both 1-14 days and 31-60 days before the individual's prediction date (3 days prior to index date, further defined below), and 2) ≥1 HD treatment both 1-7 days and 31-60 days preceding the prediction date. We excluded data from patients suspected to have COVID-19 and/or pending laboratory testing.

Software:

We used Python version 3.7.7 (Python Software Foundation, Delaware, United States) to build two ML models utilizing the XGBoost package (26) .

In the county-level model, we considered county-wide data in the general population for 4 variables and county-wide data on each local HD population based on the county of the dialysis clinic(s) for 17 a priori selected variables detailed in Table 1 and Figure 1A . The ML model was trained, validated, and tested using a random 60:20:20% split of the dataset.

In the patient-level model, we used 82 a priori selected treatment/laboratory variables (Tables 3 and 4; Figure 1B ) up to the individually defined prediction date (3 days prior to the index date defined above) to predict the risk of a SARS-CoV-2 infection being identified in the following ≥3 days. This is intended to . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131680 doi: medRxiv preprint yield individual predictions at least 3 days in advance of symptoms that warranted testing. We used a 60:20:20% randomized split of COVID-19+ samples for the training, validation, and testing datasets, and added the same number of COVID-19 negative patients to only the training and validation datasets. The testing dataset used to evaluate final model performance had a higher number of COVID-19 negative samples added to more closely match the prevalence observed in the overall national HD population.

Descriptive Statistics:

Descriptive statistics were tabulated for demographics and variables before the predicted COVID-19 outbreak in a county or HD patient SARS-CoV-2 infection.

Shapley values (27, 28) were calculated using the SHAP python package to determine the influence of each variable on model predictions (29, 30) . SHAP value is calculated for each variable and each observation, representing a measure of impact (positive or negative) of the observed value's contribution to each individual prediction. Overall feature importances for each model were calculated using the mean absolute values for each variable across all measures.

Performance of ML models was measured by the area under the receiver operating characteristic curve (AUROC) in the training, validation, and testing datasets, as well as, the recall, precision, and lift in the testing datasets (Refer to Supplementary Methods for further details). AUROC, recall, and precision metrics yield scores on a scale of 0 (lowest) to 1 (highest). Lift metric yields an estimate of how many . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131680 doi: medRxiv preprint times more/less effective the model is at predicting the outcome versus not using a model. Cutoff thresholds for classifying predictions were selected to optimize recall, precision, and lift.

Prediction of Counties with a COVID-19 Outbreak: Table 1) . Counties with a COVID-19 outbreak had a 30% higher population density compared to counties without an outbreak.

On average, the proportion of patients residing at an assisted living facility did not remarkably differ for local HD populations among counties with a major COVID-19 outbreak or not ( Table 1 ). The proportion of HD treatments with high body temperatures (>100 F) in the 14 days before a COVID-19 outbreak was <1 percentage point different between county groups. The percent change in the 14-day county-wide mean value for clinical, treatment, and laboratory parameters during the prior 28 days before a COVID outbreak was small in local HD populations and unremarkable in all cases.

Assessment of variable feature importance with SHAP values showed the top predictors of counties experiencing an outbreak were the COVID-19+ ppm in the general population during prior 7 days, . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131680 doi: medRxiv preprint number of deaths per COVID-19+ case in the general population during prior 7 days, and the change in 14-day mean pre-HD body temperature among local HD patients in prior 28 days (Figure 2A) . Figure 2B further shows the degree of positive or negative impact of each individual measurement on the prediction. For example, individual counties with a higher number of COVID-19+ ppm in the general population during prior 7 days (warmer colors) were associated with a higher SHAP value, and this was typically vice versa for individual counties with a lower number of COVID-19+ ppm (cooler colors).

The ML model had good performance in prediction of the 7-day risk for counties experiencing a COVID-19 outbreak. The AUROC for the model was 0.988, 0.799, and 0.857 in the training, validation, and testing datasets respectively (Figure 3) .

A threshold of 0.85 provided the best performance for the model within goals of limiting false positives.

In the testing dataset, the recall was 0.35 showing the model correctly predicted true positives for a COVID-19 outbreak in 35% of positive counties. The precision was 0.40 showing 40% of counties predicted to have an outbreak physically experienced a COVID-19 outbreak. The lift was 7.9 in the testing dataset, suggesting model use is 7.9 times more effective in predicting a COVID-19 outbreak in a county compared to not using a model.

Patient Characteristics:

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. In the cohort, there was a higher proportion of HD patients with a SARS-CoV-2 infection of black race, Hispanic ethnicity, and with diabetes ( Table 2) . Mean values for treatment and laboratory variables before a SARS-CoV-2 infection being identified in the subsequent ≥3 days (or concurrent index date in controls) are shown in Tables 3 & 4. HD patients who contracted COVID-19 had only subtle, clinically unremarkable distinctions in treatment/laboratory characteristics before being suspected to have a SARS-CoV-2 infection compared to unaffected patients. Mean pre-/post-HD body temperatures ( Table 3 ) and inflammatory markers (white blood cell (WBC) count and differential) ( Table 4 ) before a SARS-CoV-2 infection being identified did not did not show a clinically relevant difference differ between groups. HD patients who had a SARS-CoV-2 infection identified in the following 3 days did have higher ferritin levels compared to unaffected patients.

Calculation of variable feature importance with SHAP values found the top three predictors of HD patients having a SARS-CoV-2 infection were the patient's mean pre-HD body temperature, blood urea nitrogen (BUN), and albumin ( Figure 4A) .

The SHAP value plot is shown in (Figure 4B) . For the top predictor of mean pre-HD body temperature before a SARS-CoV-2 infection, higher body temperatures (warmer colors) were mostly associated with . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We successfully developed two ML prediction models using retrospective data that appear to have suitable performance in identifying counties at risk of a major COVID-19 outbreak in the following week and HD patients at risk of having a SARS-CoV-2 infection in the following ≥3 days. The top predictor of a COVID-19 outbreak in a county was the COVID-19+ ppm in the general population during prior week.

The top predictor of a SARS-CoV-2 infection was the individual patient's mean weekly body temperature.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131680 doi: medRxiv preprint Albeit top predictors are not surprising, the observed distinctions were subtle. Without insights from the models considering an array of variables, it would not be clear where one should classify a higher/lower risk for a county or patient that is meaningful. For instance, an increase of 0.2°F (0.1°C) observed in weekly pre-HD body temperature alone may not be considered actionable. The average pre-HD body temperature was 97.5°F (36.4°C) (primarily oral measurements) in our analysis and has been previously reported as 98.2°F (36.7°C) (31). Given 98.6°F (37°C) is the expected average in healthy populations, the lower body temperature of HD patients is of importance with the rather low incidence of fever presenting in dialysis patients with COVID-19 (11%-to-66% with fever (15, 17) ).

Prospective testing appears warranted and we anticipate combination of the county-and patient-level models may yield the greatest early insights on where and when providers can focus additional resource allocations to combat COVID-19, and what otherwise asymptomatic HD patients might be most appropriate for COVID-19 testing and triage to an isolation shift/clinic. These models have potential to provide a data-driven way for dialysis providers/clinicians to predict local transmission rates of COVID-19 and individuals with undetected infections. As more data is captured in the COVID-19 outbreak, further prediction models that can classify the risk of morbid/mortal outcomes in dialysis patients need to be developed.

The potential applications of AI for COVID-19 have been previously detailed (32); the first priority was suggested as "early detection and diagnosis of the infection". In the United States, county-level surveillance models have been developed to estimate dynamics of COVID-19 on hospital resource capacities (33) and relative risk of an emerging COVID-19 outbreak (34). Our model expands upon surveillance efforts by using advanced ML techniques to identify the risks of a COVID-19 outbreak in counties considering predictor variables specific to the HD population. The robustness of data and an a priori selection of variables to be included in both the county-and patient-level ML models bring value . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131680 doi: medRxiv preprint through assessment of feature importance; this allows for interpretation of meaningfulness of predictors, albeit it does not determine causality.

A systematic review identified several models developed using data from China for early detection of COVID-19 in suspected individuals (23) . None were designed for chronic disease populations. One is an externally validated ML model that predicts COVID-19 in suspected asymptomatic patients (AUROC validation=0.872) (35). Another effort used a prediction model (AUROC validation=0.966) to develop logic for an 8 variable COVID-19 risk chart (36). A further model with an AUROC of 0.938 was created to detect COVID-19 pneumonia in patients admitting to a fever clinic (37). Other models use genomic/computed tomography data to diagnose COVID-19 (23) . Consistent variables used across models included age, body temperature, and flu-like illness symptoms (23) . Although these models were all reported to have suitable performance, all were subject to bias due to non-generalizable sampling of controls without COVID-19 and possible overfitting. We cannot rule out that our ML models may have similar bias, although they included large samples and the testing dataset for the patient-level model had relatively generalizable sampling for the dialysis population with respect to positives/negatives (13) .

Our patient-level model is unique in its ability to identify the risk of SARS-CoV-2 infection in patients without any suspicion of being affected with the disease.

These developed models hold promise to help providers with the COVID-19 pandemic and any subsequent wave(s) of outbreak (38, 39). Nonetheless, AI modeling is never 100% accurate and model risk classifications need to be interpreted within the extent of the model's performance.

The developed AI models showed suitable performance in prediction of dialysis service areas at risk of becoming a COVID-19 hotspot and individual HD patients at risk of having an undetected SARS-CoV-2 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. 

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06. 15.20131680 doi: medRxiv preprint We would like to acknowledge Vladimir M Rigodon for assistance with the composition of the regulatory protocol for this analysis.

Project and manuscript composition were supported internally by Fresenius Medical Care.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131680 doi: medRxiv preprint the index date) and county-wide variables in general population (◊ 1-7 days before the index date; ○ difference in mean values 8-14 days to 1-7 days before the index date) for prediction of major COVID-19 outbreak in a United States county. B) Timeline of data ascertainment and prediction of HD patients with and without SARS-CoV-2 infection identified in the subsequent ≥3 days. ML model used HD treatment variables ( † mean values 1-7 days before the prediction date; ‡ difference in mean values 31-60 days to 1-7 days before the prediction date) and laboratory variables (◊ mean values 1-14 days before the prediction date; ○ difference in mean values 31-60 days to 1-14 days before the prediction date) for prediction of SARS-CoV-2 infection.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131680 doi: medRxiv preprint the positive or negative impact of each individual measurement on the prediction (x-axis), with warmer colors representing higher observed values for that measurement, and cooler colors indicating lower values for that measurement. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 17, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131680 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131680 doi: medRxiv preprint

Mitigating Risk of COVID-19 in Dialysis Facilities

COVID-19 and Dialysis Units: What Do We Know Now and What Should We Do?

Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres

Management of hemodialysis patients with suspected or confirmed COVID-19 infection: perspective of two nephrologists in the United States

Delivering safe and effective hemodialysis in patients with suspected or confirmed COVID-19 infection: a single-center perspective from Italy

USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases

Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Kidney disease is associated with in-hospital death of patients with COVID-19

Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study

Population-Based Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States

Latest data show 305 dialysis patient deaths due to COVID-19 in the US

Geographic Differences in COVID-19 Cases, Deaths, and Incidence -United States

COVID-19): Saving Lives With Caution, Care, and Courage

Epidemiology and clinical features of COVID-19: A review of current literature

An AI Epidemiologist Sent the First Warnings of the Wuhan Virus. Wired

Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel

COVID-19 and artificial intelligence: protecting health-care workers and curbing the spread

Artificial intelligence and machine learning to fight COVID-19

Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal

Coronavirus (Covid-19) Data in the United States: Data from The New York Times, based on reports from state and local health agencies. The New York Times

XGBoost: A Scalable Tree Boosting System

A Value for n-Person Games

Explaining prediction models and individual predictions with feature contributions

A Unified Approach to Interpreting Model Predictions

From local explanations to global understanding with explainable AI for trees

All variables were included in the ML prediction model to classify the risk of an individual HD patient having a SARS-CoV-2 infection being identified in the following ≥3 days

† Mean values of laboratory variables 1-14 days before the prediction date (i.e. 3 days before suspicion of SARS-CoV-2 infection in standard clinical practice)

HD: hemodialysis; Hgb: hemoglobin; WBC: white blood cell; TSAT: transferrin saturation; URR: urea reduction ratio; iPTH: intact parathyroid hormone; BUN: blood urea nitrogen; NLR: neutrophil to lymphocyte ratio; MLR: monocyte to lymphocyte ratio